DENTSPLY SIRONA Stock Price and Value Analysis

DENTSPLY SIRONA (NasdaqGS:XRAY) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold DENTSPLY SIRONA to reach your target.

Target type

XRAY Free Cash Flow Trend

Free Cash Flow trendline for XRAY
Free Cash Flow trendline for DENTSPLY SIRONA
CSV

Based on historical returns, we believe that DENTSPLY SIRONA can grow its free cash at a rate of about 5%. That's positive!

AdvantagesDisadvantages
  • This company has an average dividend yield.
  • This company has fluctuating growth.
  • This company is making money at a decent rate.
  • This stock is available at a great discount!
  • This company is very stable.
None.

Inside the XRAY Numbers

XRAY Price
(DENTSPLY SIRONA stock price per share)
$8.29
[?] XRAY Fair Price
(based on intrinsic value)
$52.53
[?] XRAY Safety Price (based on a variable margin of safety) $42.02
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 7% lower than other Healthcare stocks
[?] PE Ratio versus Industry 21% lower than other Medical Instruments & Supplies stocks
[?] Cash Yield 33.84%
[?] Free Cash Flow Jitter 30%
[?] Dividend Yield 1.88% (tax impact)
Shares Shorted 26,163,868

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 26,163,868 shares shorted. With 185,281,615 shares available for purchase and an average trading volume over the past 10 trading days of 5,933,180, it would take at least 4.4 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2007 818479 324
2008 818479 266
2009 818479 297
2010 818479 317
2011 818479 331
2012 818479 302
2013 818479 345
2014 818479 479
2015 818479 410
2016 818479 466
2017 818479 494
2018 818479 375
2019 818479 510
2020 818479 517
2021 818479 521
2022 818479 380
2023 818479 247
2024 818479 320
2025 818479 84.8

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 12 fiscal years from 2007 to 2025 with positive net income, operating cash flow totaled $5,562 million against net income of $3,626 million, or 1.53 times. Net income was negative in 7 of the 19 years, and those years are left out of the ratio.

In 2025, net income was -$598 million and operating cash flow was $235 million, so no ratio is shown for that year.

In 2025, capital expenditures were $131 million, 55.7% of operating cash flow of $235 million, which leaves an estimated $104 million after capex. Across the 19 years with reported capex, it averaged 23.5% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2007 260 388 64.2 1.49
2008 284 336 76.4 1.18
2009 274 362 56.5 1.32
2010 266 377 44.2 1.42
2011 245 393 71.2 1.61
2012 314 370 92.1 1.18
2013 313 418 100 1.33
2014 323 560 99.6 1.74
2015 251 497 72 1.98
2016 430 563 125 1.31
2017 -1,550 602 144 n/a
2018 -1,011 500 183 n/a
2019 256 639 123 2.50
2020 -73 649 87 n/a
2021 411 657 142 1.60
2022 -950 517 149 n/a
2023 -132 377 149 n/a
2024 -910 461 180 n/a
2025 -598 235 131 n/a

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2016 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $3,913 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In the 10 of those years with dividend payment facts, dividends paid totaled $957 million, 24.5% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 9 of those 10 years.

In 9 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $2,765 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, dividends paid were $128 million, 150.9% of estimated free cash flow of $84.8 million. That was more than the estimated free cash flow of the year.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2016 466 64.6 814 879 188.7%
2017 494 78.3 401 480 97.2%
2018 375 79 250 329 87.7%
2019 510 81 260 341 66.9%
2020 517 88 140 228 44.1%
2021 521 92 200 292 56.0%
2022 380 104 150 254 66.8%
2023 247 116 300 416 168.4%
2024 320 126 250 376 117.6%
2025 84.8 128 n/a 128 150.9%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $2,010 million in 2007 and $3,680 million in 2025, a compound annual growth rate of 3.4% over 18 years.

Revenue fell 3.0% from 2024 to 2025.

Our estimated free cash flow was $84.8 million in 2025, 2.3% of revenue. In 2007 the estimated margin was 16.1%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2007 2,010 324 16.1%
2008 2,191 266 12.1%
2009 2,159 297 13.7%
2010 2,221 317 14.3%
2011 2,538 331 13.0%
2012 2,928 302 10.3%
2013 2,951 345 11.7%
2014 2,923 479 16.4%
2015 2,674 410 15.3%
2016 3,745 466 12.4%
2017 3,993 494 12.4%
2018 3,986 375 9.4%
2019 4,022 510 12.7%
2020 3,339 517 15.5%
2021 4,231 521 12.3%
2022 3,922 380 9.7%
2023 3,965 247 6.2%
2024 3,793 320 8.4%
2025 3,680 84.8 2.3%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $326 million against total liabilities of $4,089 million, or 8.0% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 75.3% of total assets in 2025, compared with 41.4% in 2008, an increase of 33.9 percentage points.

Stockholders equity was $1,340 million in 2025, compared with $1,659 million in 2008, a fall of 19.2%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 2.3% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2008 2,830 204 1,171 1,659
2009 3,088 450 1,181 1,907
2010 3,258 540 1,348 1,910
2011 4,755 77.1 2,871 1,884
2012 4,972 80.1 2,723 2,249
2013 5,078 75 2,500 2,578
2014 4,647 152 2,324 2,322
2015 4,403 285 2,064 2,339
2016 11,556 384 3,430 8,126
2017 10,375 321 3,747 6,628
2018 8,687 310 3,604 5,133
2019 8,603 405 3,555 5,095
2020 9,350 438 4,415 4,935
2021 9,239 339 4,242 4,997
2022 7,643 365 3,831 3,812
2023 7,370 334 4,076 3,294
2024 5,753 272 3,810 1,943
2025 5,429 326 4,089 1,340

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $8.29, the price is below what our model can produce for average free cash flow growth between -30 and 60 percent a year, so no implied growth rate is shown. Our model assumes 5.1 percent a year for this stock. This is not a forecast of growth or a price target.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $559 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $6.63 below range
Current price $8.29 below range
20 percent above the current price $9.95 below range
Our model (stored fair price) $52.53 5.1%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

Every one of the 19 fiscal years we have for DENTSPLY SIRONA under its current filer shows positive free cash flow.

At $8.29, DENTSPLY SIRONA trades below our safe value estimate of $42.02 and our fair value estimate of $52.53.

Free cash flow from the first three years of data averaged $295 million, and from the last three $217 million: a sharp decline.

Year-to-year variability in free cash flow is uneven, measured at 30%.

Its dividend yield is 1.88%.

Our value investing guide explains how to test these numbers against the filings themselves.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 7% below the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 21% below the average for stocks in the Medical Instruments & Supplies industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Medical Instruments & Supplies industry, the ones closest in market capitalization to DENTSPLY SIRONA, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
DENTSPLY SIRONA (XRAY) 1,653 - 1.9% 33.8% 84% below
Alpha Pro Tech, Ltd. (APT) 61.2 12.2 - - 2% below
MSA Safety Incorporated (MSA) 6,550 21.8 1.2% 0.8% 277% above
The Cooper Companies (COO) 11,196 20.2 - 3.0% 17% below
Zimmer Biomet Holdings (ZBH) 19,134 25.5 0.9% - 51% above
Edwards Lifesciences Corporation (EW) 58,564 59.2 - 0.9% 148% above
Intuitive Surgical (ISRG) 138,328 48.3 - 0.6% 244% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 818479.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: XRAY annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in XRAY

Does DENTSPLY SIRONA have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: XRAY

This example shows how we apply the Trendshare checklist to XRAY: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 8.29
    • Market cap: $1.7B
    • EPS: -0.61
  2. Step 2 — Valuation checks

    • P/E: —
    • FCF yield: 33.8%
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.